In yesterday’s Wall Street session, Applied Therapeutics Inc. (NASDAQ:APLT) shares traded at $1.92, up 12.28% from the previous session.
As of this writing, 2 analysts cover Applied Therapeutics Inc. (NASDAQ:APLT). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $5.00, we find $9.50. Given the previous closing price of $1.71, this indicates a potential upside of 455.56 percent. APLT stock price is now 35.72% away from the 50-day moving average and 76.57% away from the 200-day moving average. The market capitalization of the company currently stands at $111.86M.
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $9.50 as their price target over the next twelve months.
With the price target reduced from $44 to $7, Barclays Downgraded its rating from Overweight to Equal Weight for Applied Therapeutics Inc. (NASDAQ: APLT).
In other news, Shendelman Shoshana, President and CEO sold 15,870 shares of the company’s stock on Jan 11. The stock was sold for $14,442 at an average price of $0.91. Upon completion of the transaction, the President and CEO now directly owns 751,625 shares in the company, valued at $1.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 11, Chief Medical Officer Perfetti Riccardo sold 6,053 shares of the business’s stock. A total of $5,508 was realized by selling the stock at an average price of $0.91. This leaves the insider owning 154,856 shares of the company worth $0.3 million. Insiders disposed of 26,418 shares of company stock worth roughly $50722.56 over the past 1 year. A total of 2.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in APLT stock. A new stake in Applied Therapeutics Inc. shares was purchased by SIMPLIFY ASSET MANAGEMENT INC. during the first quarter worth $4,575,000. WEALTHTRUST AXIOM LLC invested $83,000 in shares of APLT during the first quarter. In the first quarter, US BANCORP DE acquired a new stake in Applied Therapeutics Inc. valued at approximately $35,000. ESSEX FINANCIAL SERVICES, INC. acquired a new stake in APLT for approximately $19,000.
Wednesday morning saw Applied Therapeutics Inc. (NASDAQ: APLT) opened at $1.7000. During the past 12 months, Applied Therapeutics Inc. has had a low of $0.50 and a high of $2.18. The fifty day moving average price for APLT is $1.4233 and a two-hundred day moving average price translates $1.0942 for the stock.
According to the Biotechnology Company, earnings per share came in at -$0.18, beating analysts’ expectations of -$0.31 by 0.13. This compares to -$0.88 EPS in the same period last year. For the current quarter, analysts expect APLT to generate $8M in revenue.
